DCM
NVO

Dorato Capital Management’s Novo Nordisk NVO Stock Holding History

Dorato Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.24K Hold
126
– – ﹤0.01% 234
2026
Q1 		$4.74K Hold
126
– – ﹤0.01% 239
2025
Q4 		$7.42K Buy
+126
New +$6.44K 0.01% 232

Other funds holding NVO

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Dorato Capital Management's NVO Position: Q2 2026 in Review

Dorato Capital Management held its Novo Nordisk (NVO) position steady in Q2 2026 at 126 shares worth $6.24K. The position accounts for ﹤0.01% of the portfolio, ranked #234.

Dorato Capital Management first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.42K in Q4 2025. 768 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Dorato Capital Management held 126 shares of Novo Nordisk worth $6.24K as of Q2 2026.
  • Dorato Capital Management left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up ﹤0.01% of Dorato Capital Management's portfolio in Q2 2026, its #234 holding.
  • Dorato Capital Management first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • Dorato Capital Management's Novo Nordisk position peaked at $7.42K in Q4 2025.
  • 768 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Dorato Capital Management's 13F filing for Q2 2026, filed 13 Jul 2026.